Peter Spégel’s group Our researchOur research aims to understand metabolism and how it is altered in diabetes and obesity. Our hope is that knowledge on metabolic dysregulation in obesity-associated diseases and changes in metabolism associated with life-style interventions can aid us in designing sustainable life-style recommendations. The overall purpose is to enhance our understanding of metabo

https://www.ludc.lu.se/research/diabetes-obesity-and-metabolism - 2025-08-05

Karin Stenkula’s group Our researchOur research is focused on exploring the molecular mechanisms regulating adipocyte function, both normal and in the insulin-resistant state, using experimental cell biology methods and sophisticated microscopy techniques at a single cell level. AimsOur overall aim is to identify the mechanisms that cause adipocyte dysfunction. Specifically, we want to understand

https://www.ludc.lu.se/research/glucose-transport-and-protein-trafficking - 2025-08-05

Nils Wierup’s group Our researchThe purpose of our research is to understand how each islet cell type and each enteroendocrine cell type in the gut is affected in type 2 diabetes. Impaired islet function is necessary for type 2 diabetes to develop. Less is known on the role of gut hormones in type 2 diabetes pathophysiology.  By identifying type 2 diabetes-induced alterations we foresee that we wi

https://www.ludc.lu.se/research/neuroendocrine-cell-biology - 2025-08-05

Enming Zhang’s group Our researchThe deterioration of pancreatic islet cell functions is a prominent feature of diabetes. Islet cells express various cellular molecular sensors, for example ion channels. These respond to a variety of stimuli, such as voltage, chemical ligands, and mechanical/osmotic stimuli. The stimulus-sensor interactions typically regulate cellular functions to adapt to an abno

https://www.ludc.lu.se/research/diabetes-islet-pathophysiology - 2025-08-05

Harry Björkbacka’s group Cardiovascular disease is the number one cause of death in people living with diabetes, and people with diabetes are twice as likely to have heart disease or suffer a stroke than people without diabetes. Cardiovascular disease is mainly caused by atherosclerosis, which is characterized by lipid deposition, chronic inflammation, immune cell accumulation, and fibrosis of the

https://www.ludc.lu.se/research/experimental-cardiovascular-research - 2025-08-05

Lund University Diabetes Centre is home to about 30 research groups. Our scientists look for new treatments and drugs to prevent, delay, or cure diabetes. The research teams also work towards developing personalised care and treatment for patients with diabetes.  Daniel Agardh's group Anna Blom's group João Duarte’s group Isabel Goncalves' group Philipp Kaldis’ group Marju Orho-Melander’s group Pe

https://www.ludc.lu.se/research - 2025-08-05

Leaders for work package 2: Charlotte Ling and Hindrik Mulder This work package (WP2) will take advantage of the large observational cohorts with corresponding samples and will use cutting edge technology for the discovery and validation of new genetic and non-genetic biomarkers. WP2 will also use established tools for the validation of biomarker candidates recently identified by LUDC investigator

https://www.ludc.lu.se/ludc-irc/biomarker-discovery-observational-prospective-studies - 2025-08-05

Lund University Diabetes Centre (LUDC) is a research centre dedicated to unravelling the mechanisms behind diabetes and its complications. Our vision at LUDC is to improve patient stratification and to undertake innovative translational studies that lead to better prevention and management of diabetes and its complications through precision diabetes medicine.At LUDC, more than 300 people work in a

https://www.ludc.lu.se/ludc - 2025-08-05

Researchers at LUDC are part of EXODIAB (Excellence of Diabetes Research in Sweden), a strategic research area at Lund University. The aim of EXODIAB is to develop new treatments and drugs to prevent or cure diabetes. The primary aim of EXODIAB is to develop new treatments and drugs that can prevent, delay, or cure diabetes and its complications. A second objective is to create improved conditions

https://www.ludc.lu.se/ludc/exodiab-strategic-research - 2025-08-05

Lund University Diabetes Centre (LUDC) is one of the largest diabetes research centres in the world with more than 300 members of staff. LUDC is working towards improved diagnosis, prevention, and treatment of diabetes and combines expertise in several fields to achieve this goal.The research centre gathers expertise in genetics, epidemiology, statistics, bioinformatics, molecular and cellular bio

https://www.ludc.lu.se/ludc/work-ludc - 2025-08-05

Lund University Diabetes Centre (LUDC) is a world-leading research centre in the field of diabetes research. Any gift from you, regardless of amount, is a powerful endorsement of our research. Scientists at LUDC study everything from genetic factors and how they interact with the environment to disease mechanisms in the insulin-producing cells and surrounding tissue. Photo: Kennet Ruona Diabetes r

https://www.ludc.lu.se/ludc/support-us - 2025-08-05

Lund University Diabetes Centre (LUDC) is led by a governing board. The governing board includes all the principal investigators at LUDC. Allan Vaag, Coordinator of LUDC and EXODIAB, and Lena Eliasson, Vice Coordinator of LUDC and EXODIAB, handle the daily operations at LUDC. The centre is led by a governing board that includes all the principal investigators at LUDC.The strategic research area EX

https://www.ludc.lu.se/ludc/organisation - 2025-08-05

Department of Clinical Sciences Malmö Head: Martin Ridderstråle The prevalence of obesity and type 2 diabetes (T2DM) is increasing worldwide. Although our therapeutic arsenal to beget these conditions and their consequences in the form of cardiovascular morbidity and mortality is increasing a lot still needs to be learned about the underlying mechanisms. This project deals with clinical care and t

https://www.ludc.lu.se/research-0/clinical-obesity - 2025-08-05

Leaders of work package 7: Jan Nilsson and Olle Melander This work package focuses on diabetes-driven cardiovascular disease (CVD). The mild age-related diabetes (MARD) cluster, together with the mild obesity-related diabetes (MOD) and the severe insulin-resistant diabetes (SIRD) has the highest risk of developing CVD.Central to the studies in this work package are a number of well-characterised c

https://www.ludc.lu.se/ludc-irc/mild-age-related-diabetes-mard-mechanisms-and-pathways - 2025-08-05

News from the Innovation Office.

https://www.ludc.lu.se/newsletters - 2025-08-05

Leaders of work package 5: Ola Hansson and Eva Degerman SIRD is a novel form of diabetes representing the most insulin resistant (both hepatic and peripheral) form, with most features of the metabolic syndrome but also hepatic steatosis. In this work-package we explore mechanisms and pathways relevant to insulin resistance in various organs and tissues, such as liver, adipose tissue, kidney, skele

https://www.ludc.lu.se/ludc-irc/severe-insulin-resistant-diabetes-sird-mechanisms-and-pathways - 2025-08-05

Leaders of work package 1: Emma Ahlqvist and Dmytro Kryvokhyzha One of the main resources to the LUDC-IRC is the access to large well-phenotyped cohorts, which can be linked to information from the public health care system. Central to the LUDC-IRC work is the exploitation of the more refined diabetes classification, which will help us more systematically search for pathogenic mechanisms underlyin

https://www.ludc.lu.se/ludc-irc/data-harmonisation-and-integration - 2025-08-05

Leaders of work package 8: Gustav Smith and Andreas Edsfeldt LUDC-IRC takes advantage of the accumulated expertise of investigators and resources available to conduct recall trials based on pathogenetically relevant biomarkers or genotypes or based upon subtype of diabetes.Work package 8 has access to  unique, large-scale clinical cohorts that include patients with diabetes and diabetes-associated

https://www.ludc.lu.se/ludc-irc/clinical-validation-randomised-trials-and-interventions - 2025-08-05

Head: Ola Hansson Our research interest is to understand how genetic variation influences skeletal muscle function and whole-body metabolism. We use translational approaches and regularly conduct focused intervention studies in humans, including skeletal muscle biopsies. From the biopsies, muscle stem cells (satellite cells) are isolated and later used for preclinical measurements. In our projects

https://www.ludc.lu.se/research/ola-hansson - 2025-08-05

Albert Salehi’s group The etiology of metabolic syndrome and type 2 diabetes is complex and involves the interaction between both genetic and environmental factors including nutritional state with consequent metabolic signals. There are currently no clinical treatments to prevent, reverse, or efficiently cure the progression of rapid beta-cell demise or insulin resistance in diabetes-prone individ

https://www.ludc.lu.se/research/islet-cell-physiology - 2025-08-05